Taken together, these results indicate that CDK1 inhibition enhances the therapeutic efficacy of apigenin, suggesting that this combination can overcome the limited effect of apigenin and improve outcomes in subgroups of BC patients. The gene discussed is CDK1; the disease is breast cancer.